Invesco’s Genocea Biosciences, Inc. GNCA Stock Holding History

Invesco’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,627	Closed	-$4K	–	3918
2018 Q4	$4K	Sell	1,627 -92	-5%	-$458	﹤0.01%	3798
2018 Q3	$11K	Sell	1,719 -260	-13%	-$1.37K	﹤0.01%	3862
2018 Q2	$14K	Buy	+1,979	New	+$14.8K	﹤0.01%	3844
2015 Q3	–	Sell	-52	Closed	-$6K	–	4136
2015 Q2	$6K	Buy	+52	New	+$4.83K	﹤0.01%	4159

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Invesco's GNCA Position: Q1 2019 in Review

Invesco sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2019, closing a stake of 1,627 shares — an estimated $4K sold.

Invesco first reported a position in GNCA in Q2 2015 and held it in 4 quarters. The position peaked at $14K in Q2 2018. 41 funds tracked by Wall St. Rank hold GNCA as of Q1 2019.

Invesco reported no remaining Genocea Biosciences, Inc. position as of Q1 2019 after selling out during the quarter.
Invesco sold 1,627 Genocea Biosciences, Inc. shares in Q1 2019, an estimated $4K.
Invesco first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 4 quarters.
Invesco's Genocea Biosciences, Inc. position peaked at $14K in Q2 2018.
41 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2019.

Based on Invesco's 13F filing for Q1 2019, filed 15 May 2019.